Core Insights - MicroPort Medical's Firehawk® drug-eluting stent system has shown promising results in the TARGET-FIRST clinical study, allowing for a reduction in dual antiplatelet therapy duration from 12 months to 1 month for low-risk acute myocardial infarction patients without increasing ischemic risk and significantly reducing bleeding complications [1] Group 1: Clinical Research and Findings - The TARGET-FIRST study results were published in the New England Journal of Medicine and presented at the European Society of Cardiology 2025 Congress, highlighting the significance of the findings in potentially changing global clinical practices [2] - Firehawk® stent previously gained attention for addressing late thrombosis issues in a separate European trial, indicating its clinical benefits and economic potential [3] Group 2: Product Features and Design - Firehawk® is a third-generation drug-eluting stent that combines low restenosis rates with low late thrombosis rates, utilizing a unique drug release mechanism that allows for targeted and timed drug delivery [4] - The stent's design features a drug load that is one-third of conventional stents and a coating area that constitutes about 5% of the total metal area, promoting rapid endothelial healing while maintaining the stent's drug-eluting properties [4] Group 3: Market Expansion and Future Plans - Firehawk® has been introduced in 67 countries and regions across Asia, Europe, the Americas, Africa, and Oceania, with plans for commercial expansion in North America following the positive TARGET-FIRST study results [4]
微创医疗(00853)：《新英格兰医学杂志》与欧洲心脏病学大会同步发表循证医学结果，证实植入Firehawk®╱火鹰®支架低风险心肌梗死患者实际仅需1个月双抗疗程且出血并发症减少54%